This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abo T. (2001). Extrathymic pathways of T-cell differentiation and immunomodulation. Int Immunopharmacol. 7:1261–1273.
Adkins B., Charyulu V., Sun Q.L. (2000). Early block in maturation is associated with thymic involution in mammary tumor-bearing mice. J Immunol. 164:5635–5640.
Agrawal B., Krantz M.J., Reddish M.A. et al. (1998a). Cancer-associated MUC1 mucin inhibits human T cell proliferation, which reversible by IL-2. Nature Med. 4:43–49.
Agrawal B., Krantz M.J., Parker J. et al. (1998b). Expression of MUC1 mucin on activated human T cells: Implication for a role of MUC1 in normal immune regulation. Cancer Res. 58:4079–4081.
Alleva D.G., Burger C.J., Elgert K.D. (1994). Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF-β and prostaglandin E2. J Immunol. 153:1674–1679.
Altomonte M., Gloghini A., Bertola G. et al. (1993). Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53:3343–3348.
Antonia S.J., Geiger T., Miller J. et al. (1995). Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Int Immunol. 7:715–725.
Aruga A., Aruga E., Tanigawa IC. et al. (1997). Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo anti-tumor reactivity: IL-10 mediates a suppressive role. J Immunol. 159:664–673.
Barrios-Rodiles M., Tiraloche G., Chadee K. (1999). Lipopolysaccharide modulates COX2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1β and TNF-α. J Immunol. 163:963–969.
Basu S., Binder R., Suto R. et al. (2000). Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to DCs and activate the NF-B pathway. Int Immunol. 12:1539–1545.
Becker J.C., Termeer C., Schmidt R.E. et al. (1993). Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 151:7224–7232.
Beissert S., Hosoi J., Grabbe S., (1995). IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol. 154:1280–1284.
Bendelac A., Rivera M.N., Park S.H. et al. (1997). Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol. 1997;15:535–562.
Berwin B., Reed R.C., Nicchitta C.V. (2001). Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. J Biol Chem. 276:21083–21088.
Bianchi R., Grohmann U., Belladonna M. et al. (1996). 1L-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed DCs. J Immunol. 157:1589–1593.
Binder R.J., Anderson K.M., Basu S. et al. (2000). Heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol. 165:6029–6035.
Boon T., Cerottini J.C., Van den Eynde B. el al. (1994). Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:337–365.
Brichard V., Van Pel A., Wolfel T. el al. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lypmhocytes on HLA-A2 melanomas. J Exp Med. 178:489–495.
Bronte V., Apolloni E., Ronca R. et al. (2000). Genetic Vaccination with “self tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 60:253–258.
Brown C.Y., Lagnado C.A., Vadas M.A. et al. (1996). Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to IL-10. J Biol Chem. 271:2010–2018.
Bubanovic, I. (2003a). Origin of anti-tumor immunity failure in mammals and new possibility for immunotherapy. Med Hypotheses. 60:152–158.
Bubanovic I., Najman S. (2003b). Failure of Anti-tumor Immunity Mammals — Evolution of the Hypothesis. The 23rd Annual Meeting of the American Society for Reproductive Immunology. New Haven, Connecticut, USA. June 18–22, Am J Reprod Immunol. 49:329–372, Abstract N° 49; p.:351.
Bubanovic, I., (2003c). Failure of blood-thymus barrier as a mechanism of tumor and trophoblast escape. Med Hypotheses. 60:315–320.
Bubanovic I. (2003d). Crossroads of extrathymic lymphocytes maturation pathways. Med Hypotheses. 61:235–239.
Buchler T., Michalek J., Kovarova L., et al. (2003). DCs-based immunotherapy for the treatment of hematological malignancies. Hemalol. 8:97–104.
Cabestre A.E., Moreau P., Riteau B. et al. (1999). HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol. 43(2): 183–193.
Cabrera T., Angustias Fernandez M., Sierra A. et al. (1996). High frequency of altered HLA class I in invasive breast carcinomas. Human Immunol. 50:127–134.
Cammarota G. (1992). Identification of a CD4 binding site on the β2 domain of HLA-DR molecules. Nature. 356;799–801.
Cella M., Scheidegger D., Palmer-Lehmann K. et al. (1996). Ligation of CD40 on DCs triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747–751.
Cella M., Sallusto F., Lanzavecchia A. (1997). Origin, maturation and antigen presenting function of DCs. Curr Opin Immunol. 9:10–18.
Cesario T.C., Vaziri N.D., Ulich T.R. et al. (1991). Functional, biochemical, and histopathologic consequences of high-dose IL-2 administration in rats. J Lab Clin Med. 118:81–88.
Chaux P., Moutet M., Faivre J. et al. (1996). Inflammatory cells infiltrating human colorectal carcinoma express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest. 74:975–983.
Chan G., Boyle J.O., Yang E.K. et al. (1999). COX2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:991–998.
Chansky H.A., Hu M., Hickstein D.D. et al. (2001). Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61:3586–3590.
Chen W., Issazadeh S., Sayegh M.H. et al. (1997). In vivo mechanisms of acquired thymic tolerance. Cell. Immunol. 179:165–173.
Chen W., Sayegh M.H., Khouty S.J. (1998). Mechanisms of acquired thymic tolerance in vivo: inerathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy. J. Immunol. 160:1504–1508.
Chiari R., Hames G., Stroobant V. el al. (2000). Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 60:4855–4863.
Chidgey A.P., Boyd R.L. (1998). Positive selection of low responsive potentially autoreactive T cells induced by high avidity, non-deleting interactions. Int Immunol. 10:999–1008.
Colombo M., Vagliani M., Spreafico F. et al. (1996). Amount of IL 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531–2535.
Constant S.L., Bottomly K. et al. (1997). Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 15:297–322.
Coulie P.G., Karanikas V., Colau D., et al. (2001). A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 98:10290–10295.
Croft M., Carter L., Swain S.L. et al. (1994). Generation of polarized antigen-specific CD8 effector populations: reciprocal action of IL (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med. 180:1715–1728.
Cromme F.V., Airey J., Heemels M. et al. (1994). Loss of transporter protein, encoded by the TAP 1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med. 179:335–340.
Davies B., Hiby S., Gardner L. et al. (2001). HLA-G expression by tumors. Am J Reprod Immunol. 45:103–107.
Desmedt M., Rottiers, P., Dooms, H. et al. (1998). Macroph induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol. 160:5300–5308.
Di Santo J.P. (1997). Cytokines: shared receptors, distinct functions. Curr Biol. 7:424–426.
Diaz-Cazorla M., Perez-Sala D., Ros J. et al. (1999). Regulation of COX2 expression in human mesangial cells: transcriptional inhibition by IL-13. Eur J Biochem, 260:268–272.
Dowlati A., Levitan N., Remick S.C. (1999). Evaluation of IL-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med. 134:405–409.
Drexler H.G., Macleod R.A.F., Borkhardt A. et al. (1995). Recurrent chromosomal translocation and fusion genes in Leukemia-Lymphoma Cell-Lines. Leukemia. 9:303–318.
Dunn G.P., Bruce A.T., Ikeda H., et al. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998.
Enk A.H., Jonuleit H., Saloga J. et al. (1997). DCs as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 73:309–316.
Elder M.E. (1998). ZAP-70 and defects of T-cell receptor signaling. Semin Hematol. 35:310–320.
Ellison G., Waksman B. (1970). Role of the thymus in tolerance. IX. Inhibition of experimental autoallergic encephalomyelitis by intrathymic injection of encephalitogen. Immunol. 105:322–356.
Flores-Romo L. (2001). In vivo maturation and migration of DCs. Immunol. 102:255–262.
Fortis C., Foppoli M., Gianotti L. et al. (1996). Increased IL-10 serum levels in patients with solid tumours. Cancer Lett. 24;104:1–5.
Fu Y., Paul R.D., Wang Y. et al. (1998). Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. J Immunol. 143:4300–4307.
Gallucci S., Lolkema M., Matzinger P. (1999). Natural adjuvants: endogenous activators of DCs. Nat Med. 5:1249–1253.
Garrovillo M., Ali A., Oluwole S.F. et al. (1999). Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host DCs. Transplant. 68:1827–1834.
Garrido F., Cabrera T., Concha. A. et al. (1993). Natural history of HLA expression during tumor development. Immunol Today. 14:491–499.
Garrido F., Ruiz-Cabello F., Cabrera T. et al. (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 18:89–95.
Germain, R.N. (1994). MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:287–299.
Golumbek P.T., Lazenby A.J., Levitsky H.I. et al. (1991). Treatment of established renal cancer by tumor cells engineered to secrete IL-4. Science. 254:713–716.
Guo, Y., Yang, T., Liu, X. et al. (2002). Cis elements for transporter associated with antigen-processing-2 transcription: two new promoters and an essential role of the IFN response factor binding element in IFN-γ-mediated activation of the transcription initiator. Int Immunol. 14:189–200.
Hahne M., Rimoldi D., Schroter M. et al. (1996). Melanoma cell expression of fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363–1366.
Hanahan D., Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364.
Hasegawa T., Isobe K., Nakashima I. et al. (1992). Quantitative analisys of antigen for the induction tolerance in carcinoembryionic antigen transgenic mice. Immunol. 77:577–581.
Herschman H. (1996). Review: prostaglandin synthase 2. Biochim Biophys Acta. 1299:125–135.
Hosken N.A., Shibuya K., Heath A.W. et al. (1995). The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-α β-transgenic model. J Exp Med. 182:1579–1584.
Hu H.M., Urba W.J., Fox B.A. (1998). Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 161:3033–3341.
Huang M., Stolina M., Sharma S. et al. (1998). Non-small cell lung cancer COX2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of IL 10 and down-regulation of IL 12 production. Cancer Res. 58:1208–1212.
Huang S., Ullrich S.E., Bar-Eli M. et al. (1999). Regulation of tumor growth and metastasis by IL-10: the melanoma experience. J IFN Cytokine Res. 19:697–703.
Hung K., Hayashi R., Lafond-Walker A. et al. (1998). The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 88:2357–2368.
Ikebe H., Yamada H., Nomoto M., et al. (2001). Persistent infection with Listeria monocytogenes in the kidney induces anti-inflammatory invariant fetal-type γδ T cells. Immunol. 102:94–102.
Ikeda H., Ohta N., Furukawa K. et al. (1997). Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci USA. 94:6375–6379.
Jayaraman S., Luo Y., Dorf M.E. (1992). Tolerance induction in T helper (Th1) cells by thymic macrophages. J Immunol. 148:2672–2681.
Johnsen A.K., France J., Sy M.S. et al. (1999). Deficiency of TAP in tumor cells allows evasion of immune surveillance and increase tumorogenesis. J Immunol. 163:4224–4231.
Jonuleit H., Kuhn U., Müller G. et al. (1997). Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory DCs under fetal calf serum-free conditions. Eur J Immunol. 27:3135–3140.
Kaklamanis L., Leek R., Koukourakis M. et al. (1995). Loss of TAP1 protein and MHC class I molecules in primary and metastatic versus primary breast cancer. Cancer Res. 55:5191–5196.
Kawakami Y., Eliyahu S., Delgado C.H. et al. (1994). Identification of a human-melanoma antigen recognized by TIL associated with in vitro rejection. Proc Natl Acad Sci USA. 91:6458–6462.
Kim J., Modlin R.L., Moy R.L. et al., (1995). IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol. 155:2240–2245.
Kirkin A.F., thor Straten P., Zeuthen J. et al. (1996). Differential modulation by IFN-γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother. 42:203–212.
Knittler M.R., Alberts P., Deverson E.V. et al. (1999). Nucleotide binding by TAP mediates association with peptide and release of assembled MHC class I molecules. Curr Biol. 9:999–1008.
Kobata T., Azuma M., Yagita H. et al. (2000). Role of costimulatory molecules in autoimmunity. Rev Immunogenet. 2:74–80.
Kobayashi M., Kobayashi H., Pollard R. et al. (1998). A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol. 160:5869–5872.
Konig R., Huang L.Y., Germain R.N. (1992). MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature. 356;796–798.
Krasagakis K., Tholke D., Farthmann B. et al. (1998). Elevated plasma levels of TGF-β1 and TGF-β2 in patients with disseminated malignant melanoma. Br J Cancer. 77:1492–1494.
Kuchroo V.K., Das M.P., Brown J.A. et al. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:707–718.
Kufer P., Zettl F., Borschert K. et al. (2001). Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immunity. 1:10–17.
Lauritzsen G.F., Hofgaard P.O., Schenck K. et al. (1998). Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer. 78:216–222.
Liu M.A. (1997). The immunologist’s grail: Vaccines that generate cellular immunity. Proc Natl Acad Sci USA. 94:10496–10498.
Liu L., Rich B.E., Inobe J. et al. (1998). Induction of Th2 cell differentiation in the primary immune response: DCs isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol. 10:1017–1026.
Lee P.P., Zeng D., McCaulay A.E. et al. (1997). T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood. 90:1611–1617.
Lee R.S., Schlumberger M., Caillou B. et al. (1996). Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours. Eur J Cancer. 32:1233–1239.
Le Fever A., Funahashi A. (1990). Elevated prostaglandin E2 levels in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Chest. 98:1397–1402.
Lentsch A.B., Shanley T.P., Sarma V. et al. (1997). In vivo suppression of NF-kapa B and preservation of I-kapaBα by IL-10 and IL-13. J Clin Invest. 100:2443–2447.
Lobigs M., Mullbacher A., Blanden R.V. et al. (1999). Antigen presentation in syrian hamster cells: substrate selectivity of TAP controlled by polymorphic residues in TAP1 and differential requirements for loading of H2 class I molecules. Immunogenetics. 11–12:931–941.
Lowes M.A., Bishop G.A., Crotty K. et al. (1997). T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol. 108:914–919.
Luksch C.R., Winqvist O., Ozaki M.E. et al. (1999). Intercellular adhesion molecule-I inhibits IL 4 production by naive T cells. Proc Natl Acad Sci USA. 96:3023–3028.
Maeurer M.J., Lotze M.T. (1998). IL-7 knockout mice. Implications for lymphopoiesis and organ-specific immunity. Int Rev Immunol. 16:309–322.
Mantovani A., Allavena P., Vecchi A., et al. (1998). Chemokines and chemokine receptors during activation and deactivation of monocytes and DCs and in amplification of Th1 versus Th2 responses. Int J Clin Lab Res. 28:77–82.
Maki K., Sunaga S., Komagata Y. (1996). IL 7 receptor-deficient mice lack γδT cells. Proc Natl Acad Sci USA. 93:7172–7177.
Martin A., Casares F., Alonso L. et al. (1995). Changes in the blood-thymus barrier of adult rats after estradiol-treatment. Immunobiol. 192:231–248.
Masferrer J.L., Koki A. T., Seibert K. (1999). COX2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci. 889:84–86.
Matsui, M., Machida, S., Itani-Yohda, T. et al. (2002). Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by IFN-γ. J Gastroenterol Hepatol. 17:897–907.
Matsuura H., Sakaue M, Subbaramaiah K. et al. (1999). Regulation of COX2 by IFN-γ and TGF-α in normal human epidermal keratinocytes and squamous carcinoma cells: role of mitogen-activated protein kinases. J Biol Chem. 274:2913–2918.
Matzinger P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol. 12:991–1045.
Mc Lemore T.L., Hubbard W.C., Litterst C.L. et al. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res., 48:3140–3147.
Milani V., Noessner E., Ghose S. et al. (2002). Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 18:563–575.
Minghetti L., Walsh D.T., Levi G. et al. (1999). In vivo expression of COX2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J Neuropathol Exp Neurol. 58:1184–1188.
Monach P.A., Meredith S.C., Siegel C.T. et al. (1995). A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:45–59.
Moore K.W., O’Garra A., de Waal Malefyt R. et al. (1993). IL-10. Annu Rev Immunol. 11:165–190.
Mosmann T.R., Sad S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 17:138–146.
Mumberg D., Monach P.A., Wanderling S. et al. (1999). CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA. 96:8633–8638.
Murray, J.L., Hudson, J.M., Ross, M.I. et al., (2000). Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression. J Immunother. 23:28–35.
Najman S., Bubanovic I., Stamenkovic S. et al. (1990). Effects of inoculating adherent thymic cells of a donor into the thymus of a recipient on the survival of the skin graft. Acta Med Medianae. 1:79–88.
Nastala C.L., Edington H.D, McKinney T.G. et al. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-production. J Immunol. 153:1697–1701.
Niehans G.A., Brunner T., Frizelle S.P. et al. (1997). Human lung carcinomas express fas ligand. Cancer Res. 57:1007–1012.
Nieuwenhuis P., Stet R.J., Wagenaar J.P. et al. (1988). The transcapsular route: a new way for (self-) antigens to by-pass the blood-thymus barrier? Immunol Today. 9:372–375.
Niiro H., Otsuka T., Tanabe T. et al. (1995). Inhibition by IL-10 of inducible COX expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with IL-4. Blood. 85:3736–3740.
Niiro H., Otsuka T., Izuhara K. et al. (1997). Regulation by IL-10 and IL-4 of COX2 expression in human neutrophils. Blood. 89:1621–1625.
Ninomiya T., Akbar S.M., Masumoto T. (1999). DCs with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol. 31:323–331.
Nossal G.J.V. (1994). Negative selection of lymphocytes. Cell. 76:229–240.
O’ Garra A. (1998). Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 8:275–283.
Ohshima Y., Yang L.P., Uchiyama T. et al. (1998). OX40 costimulation enhances IL-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood. 92:3338–3345.
Ohteki T., Okuyama R., Seki S. et al. (1992). Age-dependent increase of extrathymic T cells in the liver and their appearance in the periphery of older mice. J Immunol. 149:1562–1570.
Page D.M., Kane L.P., Allison J.P. et al. (1993). Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol. 151:1868–1880.
Palmer E.M., van Seventer G.A. (1997). Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. J Immunol. 158:2654–2662.
Parra E., Wingren A.G., Hedlund G. et al. (1993). Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules. Scand J Immunol. 38:508–514.
Pascale P., Rouas-Freiss N., Khalil-Daher I. (1998). HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Immunol. 8:4510–4515.
Pasquini S., Xiang Z., Wang Y. et al. (1997). Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol. 75:397–401.
Paul W.E., Fathman C.G. Metzger H. (1994). Tumor Antigens Recognized by T Lymphocytes. Ann Rev Immunol. 12:337–366.
Paul P., Rouas-Freiss N., Khalil-Daher I. et al. (1998). HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 95:4510–4515.
Paul S., Bizouarne N., Paul A. et al. (1999). Lack of evidence for an immunosuppressive role for MUC1. Cancer Immunol Immunother. 48:22–28.
Pawelec G. (1999). Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother. 48:343–345.
Petersson, M., Charo, J., Salazar-Onfray, F. et al. (1998). Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol. 161:2099–2105.
Pinto M.M., Greenebaum E., Simsir A. et al. (1997). CA-125 and carcinoembryonic antigen assay vs. cytodiagnostic experience in the classification of benign ovarian cysts. Acta Cytol. 41:1456–1462.
Porter B.O., Malek T.R. (2000). Thymic and intestinal intraepithelial T lymphocyte development are each regulated by the c-dependent cytokines IL-2, IL-7, and IL-15. Semin Immunol. 12:465–474.
Ranga V., Ispas A.T. (1982). Chirulescu A.R. Elements of structure and ultrastructure of the blood-thymus barrier in ACTH involuted thymus. Acta Anat. 111:177–189.
Reddy S.T., Gilbert R.S., Xie W. et al. (1994). TGF-β linhibits both endotoxin-induced prostaglandin synthesis and expression of the TIS10/prostaglandin synthase 2 gene in murine macrophages. J Leukocyte Biol. 55:192–198.
Reiner S.L. (1995). T helper cell differentiation in immune response. Curr Opin Immunol. 7:360–366.
Restifo N.P., Esquivel F., Kawakami Y. (1993). Identification of human cancers deficient in antigen processing. J Exp Med. 177:265–272.
Rigas B., Goldman I.S., Levine L. (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:518–523.
Rivoltini L., Radrizzani M., Accomero P. et al. (1998). Human melanoma-reactive CD4+ and CD8+ CTL clones resist fas ligand-induced apoptosis and use fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220–1230.
Rosen H.R., Ausch C., Reiner G. et al. (1994). Downregulation of lymphocyte mitogenesis by breast cancer-associated p43. Cancer Lett. 82:105–111.
Rouas-Freiss N., Paul P., Dausset J. et al. (2000). HLA-G promotes immune tolerance. J Biol Regul Homeost Agents. 14:93–98.
Saha D., Datta P.K., Sheng H. et al. (1999). Synergistic induction of COX2 by TGF-β1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasm. 1:508–512.
Salazar-Onfray, F., Charo, J., Petersson, M. et al. (1997). Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol. 159:3195–3202.
Salgame P., Abrams J.S., Clayberger C. et al. (1991). Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 254:279–82.
Salomon B., Bluestone J.A. (1998). LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol. 161:5138–5142.
Sauter B., Albert M.L., Francisco L. et al. (2000). Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory DCs. J Exp Med. 191:423–429.
Scheibenbogen C., Lee K.H., Stevanovic S. et al. (1997). Analysis of the T cell response to tumor and viral peptide antigens by an IFN-γ-ELISPOT assay. Int J Cancer. 71:932–936.
Seder R.A. (1997). Are differentiated human T helper cells reversible? Int Arch Allergy Immunol. 113:163–166.
Seliger B., Harders C., Lohmann S. et al. (1998). Down-regulation of the MHC class I antigenprocessing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol. 28:122–133.
Shanker A., Singh S.M., Sodhi A. (2000). Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 2. Induction of apoptosis in thymocytes. Tumour Biol. 21:315–327.
Sharma S., Stolina M., Lin Y. (1999). T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function. J Immunol. 163:5020–5028.
Shiraki K.., Tsuji N., Shioda T. et al. (1997). Expression of fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA. 94:6420–6425.
Shimizu T., Kawamura T., Miyaji C. et al. (2000). Resistance of extrathymic T cells to stress and the role of endogenous glucocorticoids in stress associated immunosuppression. Scand J Immunol. 51:285–292.
Singh-Jasuja H., Scherer H.U., Hilf N. et al. (2000). The heat shock protein gp96 induces maturation of DCs and down-regulation of its receptor. Eur J Immunol. 30:2211–2216.
Singh-Jasuja H., Hilf N., Arnold-Schild D. et al. (2001). The role of heat shock proteins and their receptors in the activation of the immune system. Biol Chem. 382:629–636.
Steinman R.M., Banchereau J. (1998). DCs and the control of immunity. Nature. 392:245–247.
Stolina S., Sharma S., Lin Y. et al. (2000). Specific Inhibition of COX2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis. J Immunol. 164:361–370.
Strassmann G., Patil-Koota V., Finkelman F. et al. (1994). Evidence for the involvement of IL 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med. 180:2365–2370.
Swat W., Ignatowicz L., von Boehmer H. et al. (1991). Clonal deletion of immature CD4+8+ thymocytes in suspension culture by extrathymic antigen-presenting cells. Nature. 351:150–153.
Tamauchi H., Tamaoki N., Habu S. (1988). CD4+CD8+ thymocytes develop into CD4 or CD8 singlepositive cells in athymic nude mice. Eur J Immunol. 18:1859–1862.
Tao X., Constant S., Jorritsma P. et al. (1997). Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol. 159:5956–5963.
Terrazzano, G., Romano, M.F., Turco, M.C. et al. (2000). HLA class I antigen downregulation by IL (IL)-10 is predominantly governed by NK-kappaB in the short term and by TAP1 +2 in the long term. Tissue Antigens. 55:326–32.
Trinchieri G. (1995). IL-12: a pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 13:251–276.
Tsang K.Y., Zaremba S., Nieroda C.A. et al. (1995). Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 87:982–990.
Tsark E.C., Dao M.A., Wang X. et al. (2001). IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice. J Immunol. 166:170–181.
Tsujii M., Kawano S. Tsuji S. et al. (1998). COX regulates angiogenesis induced by colon cancer cells. Cell. 93:705–709.
Tsung K., Meko J.B., Peplinski G.R. et al. (1997). IL-12 induces T helper 1-directed antitumor response. J Immunol. 158:3359–3365.
Tucker O.N., Dannenberg A.J., Yang E.K. et al. et al. (1999). COX2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:987–992.
Van der Pouw Kraan T., Boeije L., Smeenk R. et al. (1995). Prostaglandin-E2 is a potent inhibitor of human IL 12 production. J Exp Med. 181:775–778.
Van den Eynde B.J., van der Bruggen P. (1997). T cell defined tumor antigens. Curr Opin Immunol. 9:684–693.
Van Waes C., Urban J.L., Rothstein J.L. et al. (1986). Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. J Exp Med. 164:1547–1565.
Vasquez N.J., Kane L.P., Hedrick S.M. (1994). Intracellular signals that mediate thymic negative selection. Immunity. 1:45–56.
Vlahos R., Stewart A.G. (1999). IL-1α and tumour necrosis factor-a modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. Br J Pharmacol. 126:1315–1320.
von Gaudecker B. (1991). Functional histology of the human thymus. Anat Embryol. 183:1–15.
von Leoprechting A., van der Bruggen P., Pahl H.L. (1999). Stimulation of CD40 on immunogenic human malignant melanomas their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 59:1287–1294.
Vu C.B. (2000). Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. Curr Med Chem. 7:1081–1100.
Ward P.L., Koeppen H.K., Hurteau T. et al. (1990). MHC class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 50:3851–3858.
Weinberg A.D., Vella AT., Croft M. (1998a). OX-40: life beyond the effector T cell stage. Semin Immunol. 10:471–480.
Weinberg AD. (1998b). Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol Med Today. 4:76–83.
Wilson D.B., Wilson D.H., Schroder K. (1998). Acquired thymic tolerance and experimental allergic encephalomyelitis in the rat. I. Parameters and analysis of possible mechanisms. Eur J Immunol. 28:2770–2779.
Wood P.J., Cossens I.A. (1993). Loss of Th1-associated function in peripheral T cells but not thymocytes in tolerance to MHC alloantigen. Immunol. 79:556–561.
Yamaguchi Y., Okabe K., Miyanari N. et al. (1998). TNF-β is associated with thymic apoptosis during acute rejection. Transplant. 66:894–902.
Yoshimatsu K., Altorki N., Golijanin D. et al. (2001). Inducible Prostaglandin E Synthase Is Overexpressed in Non-Small Cell Lung Cancer. Cancer Res. 7:2669–2674.
Yue F.Y., Dummer R., Geertsen R. et al. (1997). IL-10 is a growth factor for human melanoma cells and down-regulates HLA class I, class II and ICAM-1 molecules. Int J Cancer. 71:630–637.
Qin Z., Noffz G., Mohaupt M. et al. (1997). IL-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol. 159:770–773.
Zeidler, R., Eissner, G., Meissner, P. et al. (1997). Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded IL-10. Blood. 90:2390–2397.
Zhang L., Conejo-Garcia J.R., Katsaros D. et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213.
Zhang L., Pagano J.S. (2001). IFN regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation. Semin Cancer Biol. 11:445–453.
Zhu J., Gianni M., Kopf E. et al. (1999). Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins. Proc Natl Acad Sci USA. 96:14807–14812.
Zou G.M, Tam Y.K. (2002). Cytokines in the generation and maturation of DCs: recent advances. Eur Cytokine Netw. 13:186–199.
Zuckermann F.A. (1999). Extrathymic CD4/CD8 double positive T cells. Vet Immunol Immunopathol. 72:55–66.
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
(2004). Anti-tumor Immunity Failure in Mammals. In: Origin of Anti-Tumor Immunity Failure in Mammals. Springer, Boston, MA. https://doi.org/10.1007/0-306-48630-X_3
Download citation
DOI: https://doi.org/10.1007/0-306-48630-X_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-48629-6
Online ISBN: 978-0-306-48630-2
eBook Packages: Springer Book Archive